⌘K (Command K) to search

Sign in Sign up free

Insider · CIK 0001829899

Hammond Janet MJ

Reports to the SEC for 1 company · BOSTON, MA

Transactions

19

Companies

1

Filings

6

CIK

0001829899

Forms 4 and 5

Insider transactions

19 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-01-31	AVIRAtea Pharmaceuticals, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+58.1K sh	—	—	141,801
2026-01-31	AVIRAtea Pharmaceuticals, Inc.F Tax Payment	Chief Development Officer	FTax Payment	−14.1K sh	$4.24	−$59.9K	127,665
2026-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−46.8K sh	—	—	0
2026-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−11.3K sh	—	—	0
2026-01-31	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Development Officer	AAward	+177K sh	—	—	177,000
2025-01-31	AVIRAtea Pharmaceuticals, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+46.8K sh	—	—	84,272
2025-01-31	AVIRAtea Pharmaceuticals, Inc.A Award	Chief Development Officer	AAward	+11.3K sh	—	—	95,522
2025-01-31	AVIRAtea Pharmaceuticals, Inc.F Tax Payment	Chief Development Officer	FTax Payment	−14.1K sh	$3.06	−$43.3K	81,388
2025-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−46.8K sh	—	—	46,800
2025-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+11.3K sh	—	—	11,250
2025-01-31	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Development Officer	AAward	+200K sh	—	—	200,000
2024-02-01	AVIRAtea Pharmaceuticals, Inc.S Sale	Chief Development Officer	SSale	−14K sh	$3.84	−$53.9K	35,362
2024-01-31	AVIRAtea Pharmaceuticals, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+46.8K sh	—	—	49,391
2024-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−46.8K sh	—	—	93,600
2024-01-31	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Development Officer	AAward	+225K sh	—	—	225,200
2023-01-31	AVIRAtea Pharmaceuticals, Inc. · Restricted Stock UnitsA Award	Chief Development Officer	AAward	+140K sh	—	—	140,400
2023-01-31	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Development Officer	AAward	+197K sh	—	—	196,600
2022-01-31	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Development Officer	AAward	+190K sh	—	—	190,000
2021-01-29	AVIRAtea Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Development Officer	AAward	+160K sh	—	—	160,050

Recent filings

6

Accepted (ET)
Feb 34
Hammond Janet MJ0001193125-26-036270
SEC(opens sec.gov)
Feb 44
Hammond Janet MJ0000950170-25-013853
SEC(opens sec.gov)
Feb 24
Hammond Janet MJ0000950170-24-010967
SEC(opens sec.gov)
Feb 24
Hammond Janet MJ0000899243-23-003604
SEC(opens sec.gov)
Feb 24
Hammond Janet MJ0000899243-22-004181
SEC(opens sec.gov)
Feb 14
Hammond Janet MJ0000899243-21-003872
SEC(opens sec.gov)

Companies

1

Atea Pharmaceuticals, Inc.Chief Development OfficerAVIR

Address

225 FRANKLIN STREET SUITE 2100

BOSTON, MA, 02110